We used SEER-Medicare data to identify BMA underuse and overuse among prostate cancer patients, and then evaluated key patient, provider, and practice characteristics for association with underuse (approx. 68 percent receive BMAs appropriately) and overuse (approx. 1/3 non-candidate patients received BMA despite guidelines) [Aim 1]. We conducted in-depth interviews with prostate cancer clinicians to further understand barriers and facilitators to appropriate BMA use (analysis ongoing) [Aim 2A]. We will apply findings to refine a multi-pronged interventional strategy intended to reduce BMA underuse and overuse. Starting with a set of evidence-based healthcare interventions, we will use our findings to incorporate additional components tailored to correcting the identified barriers. We will pilot this intervention strategy within the MSK Alliance, a hybrid academic-community network of oncology providers in the Eastern US, to assess feasibility and efficacy [Aim 3].